Flexion Therapeutics, Inc. (NASDAQ:FLXN) has earned an average recommendation of “Buy” from the twelve brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $88.50.
Several brokerages recently weighed in on FLXN. Wells Fargo & Company set a $39.00 target price on Flexion Therapeutics and gave the company a “buy” rating in a research note on Monday. Northland Securities began coverage on Flexion Therapeutics in a research report on Thursday, August 24th. They issued an “outperform” rating and a $40.00 price objective for the company. Royal Bank Of Canada reissued a “buy” rating and issued a $44.00 target price on shares of Flexion Therapeutics in a report on Friday, July 7th. Zacks Investment Research cut Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Finally, Needham & Company LLC raised their price target on Flexion Therapeutics from $36.00 to $42.00 and gave the company a “buy” rating in a report on Monday, October 9th.
Flexion Therapeutics (FLXN) traded up $1.16 during mid-day trading on Friday, hitting $23.26. 798,657 shares of the company were exchanged, compared to its average volume of 3,193,008.
Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.11). analysts forecast that Flexion Therapeutics will post -3.71 EPS for the current fiscal year.
In other Flexion Therapeutics news, insider Yamo Deniz purchased 1,375 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The shares were acquired at an average price of $25.40 per share, with a total value of $34,925.00. Following the transaction, the insider now owns 5,000 shares in the company, valued at $127,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders purchased 5,375 shares of company stock worth $131,575. 15.98% of the stock is owned by insiders.
Hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp grew its stake in Flexion Therapeutics by 27.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,716,189 shares of the specialty pharmaceutical company’s stock valued at $54,921,000 after buying an additional 591,981 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in Flexion Therapeutics by 32.4% during the second quarter. Janney Montgomery Scott LLC now owns 17,970 shares of the specialty pharmaceutical company’s stock worth $363,000 after acquiring an additional 4,395 shares in the last quarter. Teachers Advisors LLC boosted its stake in Flexion Therapeutics by 3.1% during the first quarter. Teachers Advisors LLC now owns 44,796 shares of the specialty pharmaceutical company’s stock worth $1,205,000 after acquiring an additional 1,328 shares in the last quarter. Scholtz & Company LLC bought a new stake in Flexion Therapeutics during the second quarter worth about $1,131,000. Finally, Swiss National Bank boosted its stake in Flexion Therapeutics by 13.2% during the first quarter. Swiss National Bank now owns 35,911 shares of the specialty pharmaceutical company’s stock worth $966,000 after acquiring an additional 4,200 shares in the last quarter. Institutional investors own 72.31% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Analysts Set Flexion Therapeutics, Inc. (FLXN) PT at $88.50” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://sportsperspectives.com/2017/11/03/analysts-set-flexion-therapeutics-inc-flxn-pt-at-88-50.html.
About Flexion Therapeutics
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.